Pregnancy of Patients with Idiopathic Thrombocytopenic Purpura: Maternal and Neonatal Outcomes
Thrombocytopenia occurs at 7% of pregnant women. Along with other causes, idiopathic thrombocytopenic purpura (ITP) which is an autoimmune disease with autoantibodies causing platelet destruction must be considered in differential diagnosis. Antiplatelet antibodies can cross the plasenta and cause thrombocytopenia at newborn. Aim of our study is to assess management of ITP in pregnancy, and to investigate neonatal outcomes. This retrospective study was conducted in a tertiary center including 89 pregnant patients with ITP followed between October 2011 and January 2018. Patients were evaluated in two groups due to diagnosis of ITP and chronic ITP. Age, obstetric history, ITP diagnose and follow up period, presence of splenectomy, platelet count during pregnancy and after birth, treatment during pregnancy, route of delivery, weight and platelet count of newborn, sign of hemorrhage, and fetal congenital anomaly were assessed. Considering ITP and chronic ITP groups, no significant difference was seen with respect to parity, timing of delivery, preoperative and postoperative platelet counts and hemoglobin values. Route of delivery, birth weight, APGAR scores, newborn platelet count, and congenital anomaly rates were also similar. Timing of treatment were different as patiens whose diagnosis were established during pregnancy were mostly treated for preparation of delivery. Treatment modalities were similar. Probability of severe thrombocytopenia at delivery is higher in ITP patients who were diagnosed during pregnancy when compared to patients who got prepregnancy diagnosis. ITP is an important disease for both mother and newborn. Patients should be followed closely in cooperation with hematology department.